Entera Bio (ENTX) vs Rezolute (RZLT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Entera Bio (ENTX) has outperformed Rezolute (RZLT) over the past year, gaining 15.2% versus a loss of 46.8%. Over five years, RZLT leads with a -30.2% price change compared with -44.7% for ENTX. Rezolute is the larger company by market cap ($449.3 million vs $448.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENTX | RZLT |
|---|---|---|
| Share price | $2.58 | $4.65 |
| Market cap | $448.49M | $449.28M |
| 1-day change | +3.20% | +0.11% |
| YTD return | +28.87% | +96.61% |
| 1-year return | +15.21% | -46.79% |
| 5-year return | -44.69% | -30.23% |
| EPS (TTM) | $-0.36 | $-0.75 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.20 | $11.46 |
| 52-week low | $0.91 | $1.07 |
| Distance from 52-week high | -38.57% | -59.46% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +277.91% | +110.98% |
| Average volume | 1.82M | 1.50M |
| Shares outstanding | 173.83M | 96.72M |
| Employees | 20 | 58 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ENTX has outperformed RZLT by 62.0 percentage points over the past year.
About Entera Bio
ENTX stock →Entera Bio Ltd., a clinical stage company, engages in the development of oral peptides and protein replacement therapies in Israel and internationally. It develops EB613, an oral teriparatide, which completed the Phase II clinical trial for the treatment of osteoporosis and Phase I clinical trial for the treatment of stress fractures.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 20 employees
About Rezolute
RZLT stock →Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI.
Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees
ENTX vs RZLT FAQ
Which is bigger, Entera Bio or Rezolute?
Rezolute (RZLT) is larger, with a market capitalization of $449.28M compared with $448.49M for Entera Bio (ENTX).
Which stock has performed better over the past year, ENTX or RZLT?
ENTX returned +15.21% over the past 12 months, compared with -46.79% for RZLT (price return, excluding dividends). Past performance does not predict future results.
Are Entera Bio and Rezolute in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Entera Bio and Biotechnology: Pharmaceutical Preparations for Rezolute.